News - Amgen

Filter

Current filters:

Amgen

Popular Filters

1 to 25 of 153 results

Amgen’s 2nd-qtr beats expectations, but firm slashes workforce

Amgen’s 2nd-qtr beats expectations, but firm slashes workforce

30-07-2014

Amgen, the largest global independent biotech firm, reported a 23% leap in second-quarter 2014 profit…

AmgenBiotechnologyFinancialManagement

Sandoz application for biosimilar Neupogen accepted by US FDA

25-07-2014

The US Food and Drug Administration has accepted the Biologics License Application for filgrastim, which…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarzio

Amgen’s evolocumab to become gold standard among add-on statin therapies

Amgen’s evolocumab to become gold standard among add-on statin therapies

22-07-2014

Leading independent biotech firm Amgen’s investigational compound evolocumab (AMG-145) is set to become…

AmgenBiotechnologyCardio-vascularCardiovascular diseaseEuropeevolocumabMarkets & MarketingUSA

BIND Thera and Amgen end their Accurin collaboration

BIND Thera and Amgen end their Accurin collaboration

03-07-2014

US clinical stage drug developer BIND Therapeutics saw its shares plunge 15.8% to $10.84 in after-hours…

AccurinsAmgenBIND TherapeuticsBiotechnologyLicensingOncology

Breakthrough status for Amgen’s blinatumomab in ALL

01-07-2014

USA-based Amgen, the world's largest independent biotech firm, says that the US Food and Drug Administration…

AmgenBiotechnologyblinatumomabOncologyRegulationUSA

Cipla links with Hetero for biosimilar Aranesp; M&A in Yemen

30-06-2014

Cipla has collaborated with fellow Indian drugmaker Hetero to launch a biosimilar of the drug darbepoetin…

ActoriseAmgenAranespBiosimilarsCiplaGenericsHeteroIndiaMarkets & MarketingMergers & AcquisitionsOncologyRest of the World

Amgen’s Vectibix approved for colorectal cancer by FDA

Amgen’s Vectibix approved for colorectal cancer by FDA

27-05-2014

USA-based Amgen, the world's leading independent biotech firm, has announced that the US Food and Drug…

AmgenBiotechnologyChemotherapy regimensMetastatic colorectal cancerOncologyRegulationUSAVectibix

Amgen names Steven Galson, Senior Vice President, Global Regulatory Affairs and Safety

Amgen names Steven Galson, Senior Vice President, Global Regulatory Affairs and Safety

14-05-2014

US biotech firm Amgen has announced the appointment of Steven Galson to the position of senior vice president,…

AmgenBiotechnologyBoardroomUSA

Evolocumab combined with statin results in further reduction of cholesterol levels

Evolocumab combined with statin results in further reduction of cholesterol levels

14-05-2014

Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition…

AmgenBiotechnologyCardio-vascularevolocumabResearch

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study

10-05-2014

Anglo-Swedish drug major AstraZeneca and the USA’s Amgen have announced that the Phase III AMAGINE-1…

AmgenAstraZenecaBiotechnologybrodalumabInflammatory diseasesResearch

Oxford BioTherapeutics uses Amgen’s Xenomouse antibodies for breast cancer

07-05-2014

UK biotech company Oxford BioTherapeutics has obtained the exclusive global rights to USA-based Amgen’s…

AmgenBiotechnologyImmunoGenLicensingOncologyOxford BioTherapeutics

Amgen's 1st-qtr 2014 disappoints, as net income falls 25%

23-04-2014

Amgen, the world’s largest independent biotech firm by revenues, yesterday announced financial results…

AmgenBiotechnologyFinancialResearch

Pfizer palbociclib trial disappoints, despite meeting primary endpoint

Pfizer palbociclib trial disappoints, despite meeting primary endpoint

08-04-2014

At the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, US pharma giant…

AmgenOncologypalbociclibPfizerPharmaceuticalResearch

Disappointing results with Amgen’s talimogene laherparepvec in metastatic melanoma

Disappointing results with Amgen’s talimogene laherparepvec in metastatic melanoma

06-04-2014

Leading independent biotech firm Amgen has released mixed top-line results from the primary overall survival…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

Pharmaceutical companies to benefit from new blood cancer drugs

04-04-2014

Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years,…

AmgenCelgeneGilead SciencesJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRoche

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

31-03-2014

USA-based Amgen announced data at the American College of Cardiology 63rd Annual Scientific Session this…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

More positive Ph III data for Amgen’s evolocumab

More positive Ph III data for Amgen’s evolocumab

17-03-2014

Leading independent biotech firm Amgen has released more positive clinical trial data with its cholesterol…

AmgenBiotechnologyCardio-vascularevolocumabRare diseasesResearch

Retrospective analysis shows tumor shrinkage with Amgen's talimogene laherparepvec

Retrospective analysis shows tumor shrinkage with Amgen's talimogene laherparepvec

16-03-2014

Leading independent biotech firm Amgen says that findings from a pre-specified retrospective analysis…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

Nexavar disappoints in Ph III liver cancer study

Nexavar disappoints in Ph III liver cancer study

11-03-2014

German pharma major Bayer and Onyx Pharmaceuticals, now a subsidiary of US biotech firm Amgen say that…

AmgenBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

1 to 25 of 153 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top